|1.||Morin, Caroline: 3 articles (01/2015 - 09/2013)|
|2.||Fortin, Samuel: 3 articles (01/2015 - 09/2013)|
|3.||King, Irena B: 3 articles (09/2014 - 07/2010)|
|4.||Shimazu, Taichi: 2 articles (12/2015 - 12/2015)|
|5.||Sasazuki, Shizuka: 2 articles (12/2015 - 12/2015)|
|6.||Iwasaki, Motoki: 2 articles (12/2015 - 12/2015)|
|7.||Sawada, Norie: 2 articles (12/2015 - 12/2015)|
|8.||Tsugane, Shoichiro: 2 articles (12/2015 - 12/2015)|
|9.||Yamaji, Taiki: 2 articles (12/2015 - 12/2015)|
|10.||Inoue, Manami: 2 articles (12/2015 - 12/2015)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
09/01/2013 - "Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells."
03/01/2005 - "For women, a weak negative association was observed between docosapentaenoic acid and colorectal cancer risk, although it was not statistically significant. "
09/01/2013 - "The aim of the present study was to determine the anti-tumorigenic effects of docosahexaenoic acid monoglyceride (MAG-DHA), eicosapentaenoic acid monoglyceride (MAG-EPA) and docosapentaenoic acid (22:5n-3) monoglyceride (MAG-DPA) in colorectal carcinoma cells. "
03/01/2005 - "Conditional logistic regression analyses adjusted for lifestyle factors revealed that total omega-3 polyunsaturated fatty acids (odds ratio = 0.24, 95% confidence interval: 0.08, 0.76), alpha-linolenic acid (odds ratio = 0.39, 95% confidence interval: 0.16, 0.91), docosapentaenoic acid (odds ratio = 0.30, 95% confidence interval: 0.11, 0.80), and docosahexaenoic acid (odds ratio = 0.23, 95% confidence interval: 0.07, 0.76) all showed a significantly decreased risk for the highest versus the lowest quartile levels for colorectal cancer in men. "
|2.||Prostatic Neoplasms (Prostate Cancer)
09/01/2014 - "There was heterogeneity in the association between docosapentaenoic acid and prostate cancer by grade of disease (P = .006); the association was statistically significant for low-grade disease but not high-grade disease. "
01/01/2013 - "High blood level of docosapentaenoic acid (DPA) had significant negative association with total prostate cancer risk. "
09/01/2014 - "Prostate cancer risk was, respectively, 14% and 16% greater in the highest fifth of eicosapentaenoic acid (20:5n-3) (OR = 1.14, 95% CI = 1.01 to 1.29, Ptrend = .001) and docosapentaenoic acid (22:5n-3) (OR = 1.16, 95% CI = 1.02 to 1.33, P trend = .003), but in each case there was heterogeneity between studies (P = .022 and P < .001, respectively). "
|3.||Heart Diseases (Heart Disease)
08/15/2014 - "Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension."
09/01/2014 - "RBC docosapentaenoic acid (DPAn-3; C22:5n-3) was inversely associated with hs-CRP, TNF-α and the inflammation score (all P trend<0.02), whereas eicosapentaenoic acid (C20:5n-3) and docosahexaenoic acid (C22:6n-3) in RBC were not associated with inflammation (all P trend>0.18). "
01/01/2013 - "Supplementation with several EO/BO combinations increased circulating 20-22 carbon (20-22C) PUFAs, including eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and dihommo-gammalinolenic acid (DGLA), which have been shown to inhibit AA metabolism and inflammation without impacting circulating AA levels. "
01/01/2009 - "The n-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA) generally promotes inflammation, while the PUFAs of the n-3 series eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) are considered anti-inflammatory. "
01/01/2015 - "Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model."
|5.||Schizophrenia (Dementia Praecox)
01/30/2014 - "In TG, values of docosatrienoic acid (20:3n-3) and docosapentaenoic acid (20:5n-3) were significantly higher in schizophrenia patients than in controls. "
11/30/2013 - "However, we found a 34.3% decrease in docosapentaenoic acid (DPA) (22:5n-3) in patients with MDD and an 8.7% decrease in docosatetraenoic acid (22:4n-6) in those with schizophrenia, compared with controls. "
08/01/2010 - "However, docosapentaenoic acid (n-6, 22:5n-6)-PS and 22:5n-6-PC were significantly lower in individuals with schizophrenia or bipolar disorder than the controls. "
01/01/2012 - "Here, using novel statistical analysis, we show that subtle but significant abnormalities exist in the composition of fatty acids (FAs), including docosapentaenoic acid (22:5n-3), one of the omega-3 polyunsaturated FAs, found in the post-mortem frontopolar cortex (FPC) of subjects with bipolar or major depressive disorders, although not in those with schizophrenia. "
|2.||Fatty Acids (Saturated Fatty Acids)
|3.||Arachidonic Acid (Vitamin F)
|4.||Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)
|5.||alpha-Linolenic Acid (Linolenic Acid)
|6.||Linoleic Acid (Linoleate)
|7.||Omega-3 Fatty Acids (Omega 3 Fatty Acids)
|10.||F2-Isoprostanes (F2 Isoprostanes)
|1.||Renal Dialysis (Hemodialysis)